公开(公告)号：US20230228739A1

公开(公告)日：2023-07-20

申请号：US18002229

申请日：2021-07-02

Applicant: CELLECTIS S.A.

Inventor： Xenia NAJ ,  Anne-Sophie Petit ,  Roman Galetto ,  Jean-Pierre Cabaniols

IPC: G01N33/50 ,  G01N33/574 ,  G01N33/566

CPC classification number: G01N33/505 ,  G01N33/574 ,  G01N33/566 ,  G01N2800/7028

Abstract: The invention relates to a new potency assay for characterizing the quality and activity of an immune cell expressing a chimeric antigen receptor, the kit to carry out this assay and uses thereof.

公开(公告)号：US09365864B2

公开(公告)日：2016-06-14

申请号：US13900099

申请日：2013-05-22

Applicant: CELLECTIS

Inventor： Jean-Pierre Cabaniols ,  Andre Choulika ,  Christophe Delenda

IPC: C12N15/85 ,  C12N15/90

CPC classification number: C12N15/85 ,  C12N15/902

Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.

公开(公告)号：US11466291B2

公开(公告)日：2022-10-11

申请号：US16314697

申请日：2017-06-30

Applicant: CELLECTIS

Inventor： Jean-Pierre Cabaniols ,  Jean-Charles Epinat ,  Philippe Duchateau

IPC: C12N15/86 ,  C12N5/0783 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/90

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.

公开(公告)号：US20140004608A1

公开(公告)日：2014-01-02

申请号：US13900099

申请日：2013-05-22

Applicant: CELLECTIS

Inventor： Jean-Pierre Cabaniols ,  Andre Choulika ,  Christophe Delenda

IPC: C12N15/85

CPC classification number: C12N15/85 ,  C12N15/902

Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.

Abstract translation: 本发明涉及一组基因构建体，其允许通过使用大范围核酸酶在基因组中的特定位置处产生双链断裂并且因此刺激同源重组而在基因组中的固定位置有效且可重复地引入特定核苷酸序列 在该基因座位点和转染供体序列之间的事件。 本发明还涉及以试剂盒形式使用这些构建体和这些材料的方法。

公开(公告)号：US12252699B2

公开(公告)日：2025-03-18

申请号：US18480890

申请日：2023-10-04

Applicant: CELLECTIS

Inventor： Laurent Poirot ,  David Sourdive ,  Philippe Duchateau ,  Jean-Pierre Cabaniols

IPC: C12N15/85 ,  A61K35/17 ,  A61K39/00 ,  C07K14/705 ,  C07K14/74 ,  C12N5/0783 ,  C12N15/113 ,  C12N15/90

Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and/or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding B2M and/or CIITA, or by using nucleic acid molecules which inhibit the expression of B2M and/or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component.

公开(公告)号：US11820996B2

公开(公告)日：2023-11-21

申请号：US16138908

申请日：2018-09-21

Applicant: CELLECTIS

Inventor： Laurent Poirot ,  David Sourdive ,  Philippe Duchateau ,  Jean-Pierre Cabaniols

IPC: A61K35/17 ,  A61K48/00 ,  C12N5/0783 ,  C12N5/00 ,  C07K14/005 ,  C07K14/705 ,  C07K14/74 ,  C07K16/28 ,  C12N9/22 ,  C12N15/11 ,  A61K39/00 ,  C12N15/85 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N15/85 ,  C07K14/70503 ,  C07K14/70539 ,  C12N5/0636 ,  C12N15/1138 ,  C12N15/907 ,  C07K2317/24 ,  C07K2317/622

Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and/or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding B2M and/or CIITA or by using nucleic acid molecules which inhibit the expression of B2M and/or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component. In addition, expression of immunosuppressive polypeptide can be performed on those modified T-cells in order to prolong the survival of these modified T cells in host organism. Such modified T-cell is particularly suitable for allogeneic transplantations, especially because it reduces both the risk of rejection by the host's immune system and the risk of developing graft versus host disease. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer, infections and auto-immune diseases.

公开(公告)号：US11674155B2

公开(公告)日：2023-06-13

申请号：US17817877

申请日：2022-08-05

Applicant: CELLECTIS

Inventor： Jean-Pierre Cabaniols ,  Jean-Charles Epinat ,  Philippe Duchateau

IPC: C12N15/86 ,  C12N5/0783 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N15/86 ,  C12N5/0636 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/902 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2800/80

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.

公开(公告)号：US11186824B2

公开(公告)日：2021-11-30

申请号：US15556558

申请日：2016-03-11

Applicant: Cellectis

Inventor： Philippe Duchateau ,  Jean-Pierre Cabaniols ,  Julien Valton ,  Laurent Poirot

IPC: A61K35/17 ,  A61K48/00 ,  C12N5/0783 ,  C12N5/00 ,  C07K14/005 ,  C07K14/705 ,  C07K14/74 ,  C07K16/28 ,  C12N9/22 ,  C12N15/11 ,  A61K39/00

Abstract: The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.